Two latest Experts Opinion Mick Cooper, Edison
Post# of 30067
Posted On: 08/24/2014 1:13:30 PM
Two latest Experts Opinion
Mick Cooper, Edison Investment Research (8/18/14) "Commercial launch of Amarantus BioScience Holdings Inc.'s LymPro as a laboratory developed test remains on track for H2/14. The mesencephalic-astrocyte-derived neurotrophic factor has also started formal preclinical testing and could begin clinical development in 2015."
Jason Napodano, Seeking Alpha (8/6/14) "Last month Amarantus BioScience Holdings Inc. presented data on LymPro, the company's Alzheimer's disease blood test. . .a rapid and economical test like LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials. . .we believe investor expectations on the data may have gotten out of line. . .when the analysis of blood samples using version 2 of the test is conducted, we expect the results will be superior to what was seen in July. . .the current goal is on obtaining CLIA approval before the end of the year. . .we believe today is an attractive entry opportunity."
These come from the Life Science Report
http://www.thelifesciencesreport.com/pub/co/6082
Mick Cooper, Edison Investment Research (8/18/14) "Commercial launch of Amarantus BioScience Holdings Inc.'s LymPro as a laboratory developed test remains on track for H2/14. The mesencephalic-astrocyte-derived neurotrophic factor has also started formal preclinical testing and could begin clinical development in 2015."
Jason Napodano, Seeking Alpha (8/6/14) "Last month Amarantus BioScience Holdings Inc. presented data on LymPro, the company's Alzheimer's disease blood test. . .a rapid and economical test like LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials. . .we believe investor expectations on the data may have gotten out of line. . .when the analysis of blood samples using version 2 of the test is conducted, we expect the results will be superior to what was seen in July. . .the current goal is on obtaining CLIA approval before the end of the year. . .we believe today is an attractive entry opportunity."
These come from the Life Science Report
http://www.thelifesciencesreport.com/pub/co/6082
(0)
(0)